tiprankstipranks
Advertisement
Advertisement

GB:0MGB Stock Latest News

Genmab price target lowered to $38 from $40 at H.C. Wainwright
The FlyGenmab price target lowered to $38 from $40 at H.C. Wainwright
6d ago
GMAB
Genmab: Buy Rating Backed by Expanded Petosemtamab-Keytruda Phase III Trial and Blockbuster Late-Stage Pipeline
PremiumRatings
Genmab: Buy Rating Backed by Expanded Petosemtamab-Keytruda Phase III Trial and Blockbuster Late-Stage Pipeline
8d ago
GMAB
Genmab upgraded to Outperform from Neutral at BNP Paribas
PremiumThe Fly
Genmab upgraded to Outperform from Neutral at BNP Paribas
14d ago
GMAB
Genmab upgraded to Buy from Neutral at Goldman Sachs
PremiumThe Fly
Genmab upgraded to Buy from Neutral at Goldman Sachs
14d ago
GMAB
PremiumRatings
Genmab: Late‑Stage Pipeline De‑Risking and 2026 Catalysts Create Compelling 25% Upside Despite Darzalex LOE Overhang
14d ago
GMAB
Genmab reports Darzalex Q1 worldwide sales $3.964B
PremiumThe FlyGenmab reports Darzalex Q1 worldwide sales $3.964B
22d ago
JNJ
GMAB
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
Premium
Ratings
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
22d ago
GMAB
Genmab presents safety, tolerability data on Rina-S with bevacizumab
Premium
The Fly
Genmab presents safety, tolerability data on Rina-S with bevacizumab
22d ago
GMAB
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
1M ago
TW
AGX
Genmab initiated with an Outperform at Wolfe Research
PremiumThe Fly
Genmab initiated with an Outperform at Wolfe Research
1M ago
GMAB
Netflix upgraded, Pinterest downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Netflix upgraded, Pinterest downgraded: Wall Street’s top analyst calls
2M ago
AZZ
FPS
Genmab initiated with an Overweight at Wells Fargo
PremiumThe Fly
Genmab initiated with an Overweight at Wells Fargo
2M ago
GMAB
Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
PremiumRatingsGenmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
2M ago
GMAB
Genmab price target lowered to $40 from $45 at Guggenheim
Premium
The Fly
Genmab price target lowered to $40 from $45 at Guggenheim
2M ago
GMAB
Genmab: Solid Royalties and Strategic Deals, But 2026 Data Risks Justify Maintaining a Hold at $32 Target
Premium
Ratings
Genmab: Solid Royalties and Strategic Deals, But 2026 Data Risks Justify Maintaining a Hold at $32 Target
3M ago
GMAB
Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside
PremiumRatings
Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside
3M ago
GMAB
Genmab price target raised to $40 from $39 at H.C. Wainwright
PremiumThe Fly
Genmab price target raised to $40 from $39 at H.C. Wainwright
3M ago
GMAB
Genmab: Near-Term Guidance Miss Offset by Strong Results and Blockbuster Late-Stage Pipeline Upside
PremiumRatings
Genmab: Near-Term Guidance Miss Offset by Strong Results and Blockbuster Late-Stage Pipeline Upside
3M ago
GMAB
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
PremiumThe Fly
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
3M ago
JNJ
GMAB
Genmab resumed with a Buy at Jefferies
PremiumThe FlyGenmab resumed with a Buy at Jefferies
3M ago
GMAB
Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target
Premium
Ratings
Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target
3M ago
GMAB
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
Premium
Ratings
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
3M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >